105 related articles for article (PubMed ID: 10023696)
1. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
2. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
3. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
6. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
7. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum P53 antibody in patients with gastric cancer.
Shiota G; Ishida M; Noguchi N; Takano Y; Oyama K; Okubo M; Katayama S; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Ito H; Kawasaki H
Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):41-51. PubMed ID: 9523354
[TBL] [Abstract][Full Text] [Related]
10. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.
Maehara Y; Tomoda M; Hasuda S; Kabashima A; Tokunaga E; Kakeji Y; Sugimachi K
Br J Cancer; 1999 Mar; 79(7-8):1255-61. PubMed ID: 10098768
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
13. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
14. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer.
Sumiyoshi Y; Kakeji Y; Egashira A; Mizokami K; Orita H; Maehara Y
Clin Cancer Res; 2006 Sep; 12(17):5112-7. PubMed ID: 16951228
[TBL] [Abstract][Full Text] [Related]
16. Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma.
Limpaiboon T; Sripa B; Wongkham S; Bhudhisawasdi V; Chau-in S; Teerajetgul Y
Hepatogastroenterology; 2004; 51(55):25-8. PubMed ID: 15011824
[TBL] [Abstract][Full Text] [Related]
17. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
18. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
